Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEPRESCRIBE-HFpEF
NCT07298993Phase 4Enrolling by invitation
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of carvedilol in heart failure with preserved ejection fraction (HFpEF), sponsored by Weill Cornell Medicine. Started Feb 2026; status: enrolling by invitation.
02
Drugs
carvedilol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07298993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298993.